[go: up one dir, main page]

AR058841A1 - Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico - Google Patents

Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico

Info

Publication number
AR058841A1
AR058841A1 ARP060105233A ARP060105233A AR058841A1 AR 058841 A1 AR058841 A1 AR 058841A1 AR P060105233 A ARP060105233 A AR P060105233A AR P060105233 A ARP060105233 A AR P060105233A AR 058841 A1 AR058841 A1 AR 058841A1
Authority
AR
Argentina
Prior art keywords
structure similar
dendrimero
pharmaceutical interest
polymer structure
obtain conjugates
Prior art date
Application number
ARP060105233A
Other languages
English (en)
Inventor
Odio Fidel Raul Castro
Martinez Vivian Maria Saez
Hernandez Jose Angel Ramon
Sanchez Eduardo Fernandez
Meireles Rolando Paez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR058841A1 publication Critical patent/AR058841A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Una estructura polimérica semejante a dendrímero con cuatro ramas de monometoxipolietilénglicol, que puede ser representada como: (1). El grupo carboxílico de la estructura anterior puede ser funcionalizado para la obtencion de conjugados de interés farmacéutico. La union de este polietilénglicol semejante a dendrímeros a proteínas terapéuticas mejora la estabilidad in vitro e in vivo de éstas.
ARP060105233A 2005-11-30 2006-11-28 Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico AR058841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050241A CU23556A1 (es) 2005-11-30 2005-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Publications (1)

Publication Number Publication Date
AR058841A1 true AR058841A1 (es) 2008-02-27

Family

ID=37672068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105233A AR058841A1 (es) 2005-11-30 2006-11-28 Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico

Country Status (17)

Country Link
US (1) US8703893B2 (es)
EP (1) EP1967212B1 (es)
JP (1) JP5123201B2 (es)
KR (1) KR101134983B1 (es)
CN (2) CN101389354A (es)
AR (1) AR058841A1 (es)
AU (1) AU2006319636B2 (es)
BR (1) BRPI0604313A (es)
CA (1) CA2631335C (es)
CU (1) CU23556A1 (es)
EG (1) EG26619A (es)
MY (1) MY150739A (es)
RU (1) RU2409389C2 (es)
UA (1) UA91575C2 (es)
UY (1) UY29981A1 (es)
WO (1) WO2007062610A2 (es)
ZA (1) ZA200804694B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688453B2 (ja) 1986-10-03 1994-11-09 富士写真フイルム株式会社 感熱記録材料
WO2007082331A1 (en) * 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
US8252834B2 (en) * 2008-03-12 2012-08-28 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010039861A2 (en) * 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US20100158850A1 (en) * 2008-12-23 2010-06-24 The Regents Of The University Of Michigan Dendrimer based modular platforms
WO2011059609A2 (en) * 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
RU2441036C1 (ru) * 2010-09-30 2012-01-27 Общество с ограниченной ответственностью Научно-производственное объединение "Перспектива" (ООО НПО "Перспектива") Способ получения активированного полиэтиленоксида
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
CN104105508B (zh) * 2011-12-21 2017-10-24 加利福尼亚大学董事会 药物递送增强的末端树枝状聚合物
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
AU2014226741B2 (en) * 2013-03-05 2018-10-18 Hanmi Pharm. Co., Ltd. Improved preparation method for high-yield production of physiologically active polypeptide conjugate
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
WO2017030563A1 (en) 2014-08-19 2017-02-23 Biogen Ma Inc Pegylation method
CN107949565A (zh) * 2015-06-11 2018-04-20 安姆生物制药有限责任公司 聚乙二醇化粒细胞集落刺激因子(gcsf)
WO2017094897A1 (ja) 2015-12-04 2017-06-08 全薬工業株式会社 血中滞留性を改善した抗ｉｌ－１７アプタマー
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
CN115177720A (zh) 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
EP3512569A4 (en) 2016-09-15 2020-09-23 The Regents of The University of California ENHANCED HYBRID TELODENDRIMERS
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
CN109134282B (zh) * 2017-06-28 2021-03-16 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用
WO2019001473A1 (zh) * 2017-06-28 2019-01-03 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用
CN113330056A (zh) 2018-08-31 2021-08-31 加利福尼亚大学董事会 基于花青的末端树枝状共聚物及其治疗癌症的用途
CN113423384B (zh) 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
ZA951877B (en) * 1994-03-07 1996-09-09 Dow Chemical Co Bioactive and/or targeted dendrimer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP5170931B2 (ja) 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
AU2002352524B2 (en) * 2001-11-07 2007-10-04 Nektar Therapeutics Branched polymers and their conjugates
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技（上海）有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
ITMI20020951A1 (it) * 2002-05-06 2003-11-06 Univ Degli Studi Trieste Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
CN1747748B (zh) * 2003-05-23 2011-01-19 尼克塔治疗公司 具有特定原子排列的聚合物衍生物
EP1653996A2 (en) * 2003-08-08 2006-05-10 Novo Nordisk Health Care AG Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP5743368B2 (ja) * 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
KR101330338B1 (ko) * 2004-07-16 2013-11-15 넥타르 테라퓨틱스 Ｇｍ―ｃｓｆ 부분 및 중합체의 콘쥬게이트
US7714114B2 (en) * 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
CN101123992A (zh) * 2005-02-16 2008-02-13 诺和诺德公司 缀合有结构完全确定的支化聚合物的促胰岛素剂的衍生物

Also Published As

Publication number Publication date
US20090082537A1 (en) 2009-03-26
US8703893B2 (en) 2014-04-22
CN101389354A (zh) 2009-03-18
CA2631335A1 (en) 2007-06-07
CA2631335C (en) 2013-07-16
AU2006319636A1 (en) 2007-06-07
CU23556A1 (es) 2010-07-20
RU2008126209A (ru) 2010-01-10
AU2006319636B2 (en) 2012-10-18
WO2007062610A3 (es) 2007-09-20
EG26619A (en) 2014-04-08
JP5123201B2 (ja) 2013-01-23
JP2009517414A (ja) 2009-04-30
CN104906594A (zh) 2015-09-16
BRPI0604313A (pt) 2007-01-30
KR101134983B1 (ko) 2012-04-09
KR20080072960A (ko) 2008-08-07
EP1967212A2 (en) 2008-09-10
UA91575C2 (ru) 2010-08-10
MY150739A (en) 2014-02-28
UY29981A1 (es) 2007-06-29
EP1967212B1 (en) 2016-09-21
WO2007062610A2 (es) 2007-06-07
ZA200804694B (en) 2009-03-25
CN104906594B (zh) 2016-12-28
RU2409389C2 (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
AR058841A1 (es) Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico
MX2020006187A (es) Conjugados polimericos del factor viii.
Thakur et al. Impact of pegylation on biopharmaceutical properties of dendrimers
MX2012003388A (es) Acidos sulfoperoxicarboxilicos, su preparacion y metodos de uso como agentes blanqueadores y antimicrobianos.
CY1115354T1 (el) Ενωσεις πεγκυλιωμενης ινσουλινης lispro
AR078648A1 (es) Uso de nanotecnologia de dendrimeros para la administracion de biomoleculas en celulas vegetales
BR112012013664A2 (pt) rabdovírus oncolítico
WO2009016433A3 (en) Oncolytic rhabdovirus
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
CY1119954T1 (el) Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2006005058A3 (en) Polymer-factor ix moiety conjugates
WO2012116272A3 (en) Polymer conjugated protein micelles
EP4322238A3 (en) Novel reagents for directed biomarker signal amplification
WO2008079973A9 (en) Egfr binding peptides and uses thereof
AR071334A1 (es) Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
NZ592688A (en) Modified blood factors comprising a low degree of water soluble polymer
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
WO2009030065A8 (zh) 聚乙二醇修饰的干扰素α2a及其制备方法和应用
WO2008005942A3 (en) Activatable probes and methods of use
BR112012031311A2 (pt) "material polimérico conjugado e seus usos"
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
CL2010001049A1 (es) Composicion que comprende moleculas de factor estimulante de colonias de granulocitos que incluyen una molecula de polietilenglicol unida covalentemente al residuo de lisina mas cercano al extremo n-terminal; formulacion farmaceutica que la comprende; y proceso de preparacion del conjugado.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee